Voyager CEO Sandrock granted options and RSUs

Voyager Therapeutics, Inc. President and CEO Alfred Sandrock reported equity awards on February 6, 2026.

Rhea-AI Filing Summary

Voyager Therapeutics, Inc. President and CEO Alfred Sandrock reported equity awards on February 6, 2026. He received 402,500 stock options with a $3.68 exercise price, expiring on February 6, 2036, vesting monthly over four years, subject to continued service.

He was also awarded 86,250 restricted stock units, vesting in three equal annual installments starting one year after the grant date, also subject to continued service. Following these awards, he beneficially owned 522,181 shares of common stock, including 5,000 shares acquired under the company’s employee stock purchase plan.

Insider Trade Summary

Grant/Award: 488,750 shares

Grant/Award 2 txns

Insider Sandrock Alfred

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	402,500	$0.00	$0.00
Grant/Award	Common Stock	86,250	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 402,500 contracts (Direct); Common Stock — 522,181 shares (Direct)

Footnotes (3)

1. F1. Consists of shares of common stock issuable under an aggregate of 86,250 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 6, 2026. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.
2. F2. Includes 5,000 shares of common stock acquired under the Voyager Therapeutics, Inc. Amended and Restated 2015 Employee Stock Purchase Plan since the date of the reporting person's last Form 4.
3. F3. This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 6, 2026. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Voyager Therapeutics (VYGR) CEO Alfred Sandrock receive?

Alfred Sandrock received a stock option for 402,500 shares at an exercise price of $3.68 and 86,250 RSUs. Both awards were granted on February 6, 2026 under Voyager Therapeutics’ 2025 Stock Incentive Plan.

How do Alfred Sandrock’s new RSUs at Voyager Therapeutics (VYGR) vest?

The 86,250 RSUs vest over three years. One-third vests on the one-year anniversary of the February 6, 2026 grant date, and an additional one-third vests at the end of each successive one-year period, subject to his continued service.

What are the vesting terms of Alfred Sandrock’s new Voyager Therapeutics (VYGR) stock options?

The option for 402,500 shares vests over four years. 1/48th of the shares vest one month after the February 6, 2026 grant date, with an additional 1/48th vesting monthly thereafter, subject to continued service, and expires on February 6, 2036.

What is Alfred Sandrock’s reported Voyager Therapeutics (VYGR) share ownership after these awards?

After the reported transactions, Alfred Sandrock beneficially owned 522,181 shares of common stock. This figure includes 5,000 shares acquired under the Voyager Therapeutics Amended and Restated 2015 Employee Stock Purchase Plan since his prior Form 4 filing.

Were Alfred Sandrock’s Voyager Therapeutics (VYGR) equity awards granted for cash consideration?

The Form 4 lists both the 402,500 stock options and 86,250 RSUs with a transaction price of $0.00. The options have an exercise price of $3.68 per share, payable upon exercise, while RSUs convert to shares upon vesting.

Under which plans were Alfred Sandrock’s Voyager Therapeutics (VYGR) equity positions reported?

The 86,250 RSUs and 402,500 stock options were granted under the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan. His ownership also includes 5,000 shares acquired through the company’s Amended and Restated 2015 Employee Stock Purchase Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/10/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sandrock Alfred

(Last) (First) (Middle)

C/O VOYAGER THERAPEUTICS, INC.

75 HAYDEN AVENUE

(Street)

LEXINGTON MA 02421

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Voyager Therapeutics, Inc. [ VYGR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/06/2026		A		86,250(1)	A	$0.00	522,181(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.68	02/06/2026		A		402,500		(3)	02/06/2036	Common Stock	402,500	$0.00	402,500	D

Explanation of Responses:

1. Consists of shares of common stock issuable under an aggregate of 86,250 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 6, 2026. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.

2. Includes 5,000 shares of common stock acquired under the Voyager Therapeutics, Inc. Amended and Restated 2015 Employee Stock Purchase Plan since the date of the reporting person's last Form 4.

3. This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 6, 2026. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.

	/s/ Gregory Shiferman, as Attorney-in-Fact for Alfred Sandrock	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.